Staff Member Biography

Elisabeth Fenwick

position: Senior Lecturer in Health Economics programme: Cross-Programme

Contact Details

email:
phone: 0141 330 4039

Address

Public Health & Health Policy,
University of Glasgow,
1 Lilybank Gardens,
Glasgow, G12 8RZ

Biography and Interests

Elisabeth Fenwick joined the unit in 2006 as a joint appoitment with Health Policy at the University of Glasgow. A health economist, her role is to provide economic evaluation input into a variety of projects within the unit. Liz has an M.Sc. and PhD in Health Economics from the University of York and an M.Sc. in Operations Research from the University of Southampton. During 2002/03 she spent a year as a visiting Postdoctoral Fellow at the Centre for Evaluation of Medicines (CEM), at McMaster University, Canada.

Her research interests centre around the application of decision analytic modelling to economic evaluation, probabilistic decision analytic modelling, Bayesian decision theory and value of information analysis. Her thesis presented an iterative framework for the efficient management of the HTA process incorporating probabilistic decision analytic modelling, value of information analysis and Bayesian updating. Her current research includes expanding this framework to incorporate and assess the value of implementation strategies.

Click for further information on Dr Elisabeth Fenwick

Publications

Lawson KD, Fenwick E, Pell ACH, Pell JP. Comparison of mass and targeted screening strategies for cardiovascular risk: Simulation of the effectiveness, cost-effectiveness and coverage from a cross sectional survey of 3,291 people. Heart 2010; 96:208-12.

Lorgelly P, Lawson K, Fenwick E, Briggs A. Outcome measurement in economic evaluations of public health interventions: a role for the capability approach? International Journal of Environmental Research and Public Health 2010; 7:2274-89.

Hoomans T, Fenwick E, Palmer S, Claxton K. Value of information and value of implementation: Application of an analytical framework to inform resource allocation decisions in Metastatic Hormone-Refractory Prostate Cancer. Value in Health 2009; 12:315-24.

pubmed open access

Barton G, Briggs A, Fenwick E. Optimal cost-effectiveness decisions: The role of the Cost-Effectiveness Acceptability Curve (CEAC), the Cost-Effectiveness Acceptability Frontier (CEAF), and the Expected Value of Perfection Information (EVPI). Value in Health 2008; 11:886-97.

pubmed open access

Fenwick E, Claxton K, Sculpher M. The value of implementation and the value of information: combined and uneven development. Medical Decision Making 2008; 28:21-32.
pubmed

Fenwick E, Marshall D, Blackhouse G, Vidaillet H, Slee A, Shermanski L, Levy AR. Assessing the impact of censoring of costs and effects on health care decision-making: an example using the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Value in Health 2008; 11:365-73.

pubmed open access

Fitzsimons C, Baker G, Wright A, Nimmo M, Ward Thompson C, Lowry R, Millington C, Shaw R, Fenwick E, Ogilvie D, Inchley J, Foster C, Mutrie N, Scottish Physical Activity Research Collaboration. The ‘Walking for Wellbeing in the West’ randomised controlled trial of a pedometer-based walking programme in combination with a physical activity consultation with 12 month follow-up: rationale and study design. BMC Public Health 2008; 8:259.
pubmed open access

Lorgelly PK, Lorimer K, Fenwick E, Briggs AH. The Capability Approach: developing an instrument for evaluating public health interventions: Final report. Glasgow: Glasgow Centre for Population Health, 2008.

open access

Asseberg C, Bravo Y, Palmer S, Fenwick E, de Belder M, Abrams K, Sculpher M. Assessing the effectiveness of primary angioplasty compared to thrombolysis and its relationship to time delay: a Bayesian evidence synthesis. Heart 2007; 93:1244-50.
pubmed

Bravo Vergel Y, Palmer S, Asseburg C, Fenwick E, de Belder M, Abrams K, Sculpher M. Is primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis. Heart 2007; 93:1238-43.
pubmed

Collins R, Fenwick E, Trowman R, Perard R, Norman G, Light K, Birtle A, Palmer A, Riemsma R. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technology Assessment 2007; 11: iii-iv, xv-xviii, 1-179.
pubmed

Fenwick E, Briggs A. Cost-effectiveness acceptability curves in the dock: Case not proven? Medical Decision Making 2007; 27:93-95.
pubmed

Claxton K, Fenwick E, Sculpher M. Decision-making with uncertainty: the value of information. In: Jones AM, ed. Elgar Companion to Health Economics. Cheltenham: Elgar Publishing, 2006:514-525.

Collins R, Trowman R, Norman G, Light K, Birtle A, Fenwick E, Palmer S, Riemsma R. A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer. British Journal of Cancer 2006; 95:457-462.

Fenwick E, Marshall DA, Levy AR, Nichol G. Using and interpreting cost-effectiveness acceptability curves: An example using data from a trial of management strategies for atrial fibrillation. BMC Health Services Research 2006; 6:52.
pubmed

Fenwick E, Palmer S, Claxton K, Sculpher M, Abrams K, Sutton A. An iterative Bayesian approach to health technology assessment: Application to a policy of pre-operative optimisation for patients undergoing major elective surgery. Medical Decision Making 2006; 26:480-496.

Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. British Journal of Psychiatry 2005; 187:106-108.
pubmed

Fenwick E, Claxton K, Sculpher M. The value of implementation and the value of information: combined and uneven development, 2005.

O'Hagan A, McCabe C, Akehurst R, Brennan A, Briggs A, Claxton K, Fenwick E, Fryback D, Sculpher M, Spiegelhalter D, Willan A. Incorporation of uncertainty in health economic modelling studies. Pharmacoeconomics 2005; 23:529-536.
pubmed

Severens JL, Brunenberg DEM, Fenwick E, O'Brien B, Joore MA. Cost-effectiveness acceptability curves and a reluctance to lose. Pharmacoeconomics 2005; 23:1207-1214.
pubmed

Claxton K, Fenwick E, Palmer S, Sculpher M, Abrams K, Sutton A. Building a reference case for Bayesian applications to health economics and outcomes research. Report to the Bayesian Initiative, 2004.

Fenwick E, O'Brien B, Briggs A. Cost-effectiveness acceptability curves-Facts, fallacies and FAQ. Health Economics 2004; 13:405-415.

Marshall D, Levy AR, Vidaillet H, Fenwick E, Slee A, Blackhouse G, Greene HL, Wyse DG, Nichol G, O'Brien BJ, AFFIRM Investigators, Investigators C. Cost-effectiveness of rhythm versus rate control in atrial fibrillation. Annals of Internal Medicine 2004; 141:653-661.
open access

Fenwick E, Claxton K, Sculpher M, wilson RJ. Pre-operative optimisation employing dopexamine or adrenaline for patients undergoing major elective surgery: A cost-effectiveness analysis. Intensive Care Medicine 2002; 28:599-608.

Fenwick E, Claxton K, Sculpher M. Representing uncertainty: The role of cost-effectiveness acceptability curves. Health Economics 2001; 10:779-787.